Experienced in Opioid Use Disorder

Dr. Harshavardhan R. Krishna

Internal Medicine
Health First Medical Center Plc
12100 Dix Toledo Rd, 
Southgate, MI 
Accepting New Patients
Experienced in Opioid Use Disorder
Health First Medical Center Plc
12100 Dix Toledo Rd, 
Southgate, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Harshavardhan Krishna is a primary care provider, practicing in Internal Medicine in Southgate, Michigan. Dr. Krishna is rated as an Experienced provider by MediFind in the treatment of Opioid Use Disorder. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Sitosterolemia, and Opioid Induced Constipation. Dr. Krishna is currently accepting new patients.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in MI
Hospital Affiliations
Wyandotte Hospital And Medical Center
Languages Spoken
English
Hindi
Telugu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

HEALTH FIRST MEDICAL CENTER PLC
12100 Dix Toledo Rd, Southgate, MI 48195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Opioid Use Disorder
Dr. Pooja A. Lagisetty
Internal Medicine
Distinguished in Opioid Use Disorder
Dr. Pooja A. Lagisetty
Internal Medicine
1500 E Medical Center Drive, 3rd Floor Taubman Center Recp B, 
Ann Arbor, MI 
 (27.7 miles away)
734-936-5582
Languages Spoken:
English
See accepted insurances

Pooja Lagisetty is a primary care provider, practicing in Internal Medicine in Ann Arbor, Michigan. Dr. Lagisetty is rated as a Distinguished provider by MediFind in the treatment of Opioid Use Disorder. Her top areas of expertise are Opioid Use Disorder, Chronic Pain, Acute Pain, and Fibromyalgia.

Advanced in Opioid Use Disorder
Dr. Talal T. Khader
Internal Medicine
Advanced in Opioid Use Disorder
Dr. Talal T. Khader
Internal Medicine

Pelham Primary Care PC

3815 Pelham St, Suite 5, 
Dearborn, MI 
 (4.7 miles away)
313-789-7636
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Talal Khader is a primary care provider, practicing in Internal Medicine in Dearborn, Michigan. Dr. Khader is rated as an Advanced provider by MediFind in the treatment of Opioid Use Disorder. His top areas of expertise are Multiple Carboxylase Deficiency, Folate Deficiency, Vitamin B12 Deficiency Anemia, Gastrostomy, and Bone Marrow Aspiration. Dr. Khader is currently accepting new patients.

Advanced in Opioid Use Disorder
Dr. Joseph A. George
Family Medicine | Internal Medicine
Advanced in Opioid Use Disorder
Dr. Joseph A. George
Family Medicine | Internal Medicine
2333 Biddle Ave, 
Wyandotte, MI 
 (2.5 miles away)
313-386-3200
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph George is a primary care provider, practicing in Family Medicine and Internal Medicine in Wyandotte, Michigan. Dr. George is rated as an Advanced provider by MediFind in the treatment of Opioid Use Disorder. His top areas of expertise are Opioid Use Disorder, Bronchiolitis Obliterans, Industrial Bronchitis, Vertebroplasty, and Bone Graft. Dr. George is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishna's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile